ApoA-IV Serum Prediction for Chronic Kidney Disease Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective predictors for chronic kidney disease progression, particularly in non-diabetic patients, with unclear contributions from dyslipidemia and ambiguous results from previous studies, necessitating a reliable method to assess disease progression.
Innovation Solution
A method involving the determination of apolipoprotein A-IV (ApoA-IV) concentration in serum, using enzyme-linked immunosorbent assay (ELISA), in conjunction with glomerular filtration rate (GFR) and apolipoprotein E genotype, to predict chronic kidney disease progression, specifically identifying elevated ApoA-IV levels and reduced GFR as predictors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional lipid metabolism markers are used to predict chronic kidney disease progression, then the prediction method is simple and widely available, but the prediction accuracy and reliability are insufficient due to ambiguous results from previous studies
Solution Approach 1:
The invention shifts from measuring conventional lipid parameters (total cholesterol, LDL, HDL, triglycerides) to measuring apolipoprotein A-IV concentration, a different parameter within the lipid metabolism pathway. This parameter change provides superior predictive accuracy for CKD progression while maintaining compatibility with standard laboratory measurement techniques
Solution Approach 2:
Apolipoprotein A-IV serves as an intermediary marker that connects lipid metabolism abnormalities to kidney disease progression. Rather than directly measuring kidney function or using complex multi-parameter models, ApoA-IV acts as a reliable intermediary predictor that simplifies the assessment while improving accuracy compared to conventional lipid markers
2Reliability
If multiple lipid parameters are measured to assess dyslipidemia contribution, then comprehensive lipid profile is obtained, but the results remain ambiguous and fail to provide reliable progression prediction
Solution Approach 1:
The invention extracts ApoA-IV from the complex panel of lipid parameters and identifies it as the single most reliable predictor of CKD progression. This extraction approach eliminates the ambiguity associated with measuring multiple lipid parameters simultaneously, providing clear and reliable progression prediction based on a single critical marker
3Measurement precision
If long-term prospective follow-up studies with multiple parameters are conducted, then reliable prediction models can be established, but the study complexity and resource requirements increase significantly
Solution Approach 1:
The invention performs preliminary identification of ApoA-IV as the critical predictive marker before conducting large-scale prospective studies. By establishing ApoA-IV's predictive value in earlier studies, the invention enables future research to focus on this single parameter, significantly reducing the complexity and resource requirements of long-term prospective follow-up studies while maintaining high measurement precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively predicts chronic kidney disease progression by demonstrating that elevated ApoA-IV concentrations and reduced GFR are significant predictors, with ApoA-IV levels above the median associated with faster progression and GFR being a strong predictor, providing a novel independent predictor of disease progression.
Implementation Method 1
The serum level of Apo-AIV is inversely correlated to the glomerular filtration rate and kidney functioning
Data Source
Figure 1
Figure 2
AI summary
The present invention refers to a method for identifying a chronic kidney disease progression in a subject, preferably for predicting a non-diabetic chronic disease progression, comprising a determination of apolipoprotein A-IV (ApoA-IV) in a sample, preferably a determination of apoA-IV concentration in blood plasma or serum. The present invention further refers to a use of said method.